Published in Arch Virol on January 01, 1986
Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection. Antimicrob Agents Chemother (2006) 2.69
Differential mechanisms of complement-mediated neutralization of the closely related paramyxoviruses simian virus 5 and mumps virus. Virology (2008) 1.06
Cell- and Protein-Directed Glycosylation of Native Cleaved HIV-1 Envelope. J Virol (2015) 0.97
The paramyxoviruses simian virus 5 and mumps virus recruit host cell CD46 to evade complement-mediated neutralization. J Virol (2009) 0.92
Attachment of human polymorphonuclear leukocytes to herpes simplex virus-infected fibroblasts mediated by antibody-independent complement activation. J Virol (1988) 0.92
Complement-mediated binding of naturally glycosylated and glycosylation-modified human immunodeficiency virus type 1 to human CR2 (CD21). J Virol (1993) 0.92
Virion-associated complement regulator CD55 is more potent than CD46 in mediating resistance of mumps virus and vesicular stomatitis virus to neutralization. J Virol (2012) 0.82
Point mutations in the paramyxovirus F protein that enhance fusion activity shift the mechanism of complement-mediated virus neutralization. J Virol (2013) 0.79
The neutralizing capacity of antibodies elicited by parainfluenza virus infection of African Green Monkeys is dependent on complement. Virology (2014) 0.76
An AGM model for changes in complement during pregnancy: neutralization of influenza virus by serum is diminished in late third trimester. PLoS One (2014) 0.75
Complement Evasion Strategies of Viruses: An Overview. Front Microbiol (2017) 0.75
Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol (2001) 24.36
Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet (1987) 3.79
Treatment of multiple sclerosis with gamma interferon: exacerbations associated with activation of the immune system. Neurology (1987) 3.11
Heat labile opsonins to Pneumococcus. 3. The participation of immunoglobulin and of the alternate pathway of C3 activation. J Immunol (1972) 2.89
Slow virus replication: the role of macrophages in the persistence and expression of visna viruses of sheep and goats. J Gen Virol (1982) 2.87
Deficiency of pneumococcal serum opsonizing activity in sickle-cell disease. N Engl J Med (1968) 2.61
Activation of the alternative complement pathway by pneumococcal cell wall teichoic acid. J Immunol (1978) 2.40
A multiinstitutional survey of the Wiskott-Aldrich syndrome. J Pediatr (1994) 2.39
Myasthenia gravis. Study of humoral immune mechanisms by passive transfer to mice. N Engl J Med (1977) 2.23
Nonvenereal transmission of gonococcal infections to children. J Pediatr (1971) 2.06
Surface determinants of Haemophilus influenzae pathogenicity: comparative virulence of capsular transformants in normal and complement-depleted rats. J Infect Dis (1983) 2.06
The role of complement in the host's defense against Streptococcus pneumoniae. Rev Infect Dis (1981) 2.06
Activation of the alternative pathway by pneumococcal cell walls. J Immunol (1977) 1.89
Francisella philomiragia sepsis in chronic granulomatous disease. Pediatr Infect Dis J (1997) 1.88
X-linked agammaglobulinemia: an analysis of 96 patients. Medicine (Baltimore) (1985) 1.85
Improved identification of intracortical lesions in multiple sclerosis with phase-sensitive inversion recovery in combination with fast double inversion recovery MR imaging. AJNR Am J Neuroradiol (2007) 1.83
H reflex studies in cerebral palsy patients undergoing partial dorsal rhizotomy. Muscle Nerve (1994) 1.83
The role of the capsular polysaccharide in the activation of the alternative pathway by the pneumococcus. J Immunol (1976) 1.80
Pseudomonas cepacia: an emerging pathogen in chronic granulomatous disease. J Pediatr (1986) 1.79
Standardized MR imaging protocol for multiple sclerosis: Consortium of MS Centers consensus guidelines. AJNR Am J Neuroradiol (2006) 1.78
Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes". Neurology (2001) 1.76
The role of immunoglobulin in the interaction of pneumococci and the properdin pathway: evidence for its specificity and lack of requirement for the Fc portion of the molecule. J Immunol (1974) 1.73
Chronic rotavirus infection in immunodeficiency. J Pediatr (1980) 1.66
Carrier detection in X-linked agammaglobulinemia by analysis of X-chromosome inactivation. N Engl J Med (1987) 1.63
Herpes zoster ophthalmicus and delayed contralateral hemiparesis caused by cerebral angiitis: diagnosis and management approaches. Ann Neurol (1983) 1.60
Variable results after rituximab in neuromyelitis optica. J Neurol Sci (2012) 1.58
Host defense molecule polymorphisms influence the risk for immune-mediated complications in chronic granulomatous disease. J Clin Invest (1998) 1.58
Familial clustering of hepatitis B infection. N Engl J Med (1973) 1.56
Activation of C3 via the alternative complement pathway results in fixation of C3b to the pneumococcal cell wall. J Immunol (1980) 1.54
Ethics of placebo-controlled clinical trials in multiple sclerosis: a reassessment. Neurology (2008) 1.53
Sarcoidosis and common variable immunodeficiency. Report of 8 cases and review of the literature. Medicine (Baltimore) (1996) 1.53
Entry overload, emergency department overcrowding, and ambulance bypass. Emerg Med J (2003) 1.52
Linomide in relapsing and secondary progressive MS: part I: trial design and clinical results. North American Linomide Investigators. Neurology (2000) 1.52
Measles encephalomyelitis--clinical and immunologic studies. N Engl J Med (1984) 1.50
The challenge of follow-on biologics for treatment of multiple sclerosis. Neurology (2009) 1.49
Copolymer 1: a most reasonable alternative therapy for early relapsing-remitting multiple sclerosis with mild disability. Neurology (1995) 1.48
Activation of the alternative complement pathway by Haemophilus influenzae type B. Infect Immun (1977) 1.46
Hepatitis B antigen and antibody in blood donors: an epidemiologic study. J Infect Dis (1973) 1.46
The complement system: its importance in the host response to viral infection. Microbiol Rev (1982) 1.44
Acquired toxoplasmosis. A neglected cause of treatable nervous system disease. Arch Neurol (1975) 1.44
Immunochemical identification of rubella virus hemagglutinin. Virology (1983) 1.44
Consequences of the delayed diagnosis of ataxia-telangiectasia. Pediatrics (1998) 1.44
Opsonins: their function, identity, and clinical significance. J Pediatr (1973) 1.42
Platelet activating factor inhibition reduces lung injury after cardiopulmonary bypass. Ann Thorac Surg (1995) 1.42
Relationship of urinary myelin basic protein-like material with cranial magnetic resonance imaging in advanced multiple sclerosis. Arch Neurol (2001) 1.40
Neutrophil depletion limited to reperfusion reduces myocardial infarct size after 90 minutes of ischemia. Evidence for neutrophil-mediated reperfusion injury. Circulation (1989) 1.40
3D MPRAGE improves classification of cortical lesions in multiple sclerosis. Mult Scler (2008) 1.39
The relationship of MS to physical trauma and psychological stress: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology (1999) 1.38
The effect of complement depletion on the course of Sindbis virus infection in mice. J Immunol (1978) 1.38
The role of C3 as an opsonin in the early stages of infection. Proc Soc Exp Biol Med (1975) 1.38
Sequence determination of the mumps virus HN gene. Virology (1988) 1.38
Effects of seasons on magnetic resonance imaging--measured disease activity in patients with multiple sclerosis. Ann Neurol (2001) 1.35
Reconstitution of B and T lymphocyte function in severe combined immunodeficiency disease after transplantation with thymic epithelium. Lancet (1976) 1.35
Characterization and virulence analysis of catalase mutants of Haemophilus influenzae. Infect Immun (1994) 1.34
Pathophysiology of multiple sclerosis and the place of teriflunomide. Acta Neurol Scand (2010) 1.34
Carrier detection in the Wiskott Aldrich syndrome. Blood (1988) 1.32
Neutralizing antibody spectrum determines the antigenic profiles of emerging mutants of visna virus. Infect Immun (1981) 1.31
The contribution of magnetic resonance imaging to the diagnosis of multiple sclerosis. Neurology (1999) 1.31
Oral administration of human serum immunoglobulin in immunodeficient patients with viral gastroenteritis. A pharmacokinetic and functional analysis. J Clin Invest (1985) 1.31
Primary culture of capillary endothelium from rat brain. In Vitro (1981) 1.30
MRI T2 lesion burden in multiple sclerosis: a plateauing relationship with clinical disability. Neurology (2006) 1.29
Participation of complement in the nonimmune host defense against experimental Haemophilus influenzae type b septicemia and meningitis. Infect Immun (1976) 1.29
Conversion of nonfusing mumps virus infections to fusing infections by selective proteolysis of the HN glycoprotein. Virology (1983) 1.28
Progressive rubella panencephalitis. Late onset after congenital rubella. N Engl J Med (1975) 1.28
Biochemical features of mumps virus neuraminidases and their relationship with pathogenicity. Virology (1981) 1.27
Detailed immunologic analysis of the structural polypeptides of rubella virus using monoclonal antibodies. Virology (1985) 1.26
Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM(197) among infants with sickle cell disease. Pneumococcal Conjugate Vaccine Study Group. Pediatrics (2000) 1.26
Neuronal and oligodendroglial infection by the WW strain of Theiler's virus. Lab Invest (1979) 1.25
Oropharyngeal dysphagia and aspiration in patients with ataxia-telangiectasia. J Pediatr (2000) 1.25
A dual approach for minimizing false lesion classifications on magnetic resonance images. Magn Reson Med (1997) 1.24
The role of complement in viral infections. II. the clearance of Sindbis virus from the bloodstream and central nervous system of mice depleted of complement. J Infect Dis (1980) 1.23
Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group. Mult Scler (2000) 1.23
Protective effects of glycoprotein-specific monoclonal antibodies on the course of experimental mumps virus meningoencephalitis. J Virol (1985) 1.23
Cloning and sequencing of the mumps virus fusion protein gene. Virology (1987) 1.20
Development of antibody to measles virus polypeptides during complicated and uncomplicated measles virus infections. J Virol (1984) 1.20
The role of complement in viral infections. III. Activation of the classical and alternative complement pathways by Sindbis virus. J Immunol (1980) 1.20
Host modification of Sindbis virus sialic acid content influences alternative complement pathway activation and virus clearance. J Immunol (1981) 1.19
A fusing mumps virus variant selected from a nonfusing parent with the neuraminidase inhibitor 2-deoxy-2,3-dehydro-N-acetylneuraminic acid. Virology (1986) 1.18
Cellular immune responses during complicated and uncomplicated measles virus infections of man. Clin Immunol Immunopathol (1984) 1.18
Virus-specific intracytoplasmic inclusions in mouse brain produced by a newly isolated strain of Theiler virus. I. Virologic and morphologic studies. Lab Invest (1977) 1.18
Enzyme-linked immunosorbent assay for detection and quantitation of capsular antigen of Haemophilus influenzae type b. Infect Immun (1978) 1.15
Adenosine deaminase deficiency in adults. Blood (1997) 1.15
Isolation of metabolically active capillaries from rat brain. J Neurochem (1975) 1.15
Complement and the host's defense against the pneumococcus. Crit Rev Microbiol (1984) 1.15
A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients. Mult Scler (2006) 1.15
Defective antigen-induced lymphocyte proliferation in the X-linked hyper-IgM syndrome. J Pediatr (1997) 1.14
Determinants of overall quality of life in secondary progressive MS: a longitudinal study. Neurology (2001) 1.13
Lack of protective effect of autotransplanted splenic tissue to pneumococcal challenge. Blood (1978) 1.12
Postinfectious leukoencephalitis complicating Mycoplasma pneumoniae infection. Arch Neurol (1983) 1.12
Thymopentin therapy reduces the clinical severity of atopic dermatitis. J Allergy Clin Immunol (1990) 1.10
Adenine arabinoside in the treatment of progressive multifocal leukoencephalopathy: use of virus-containing cells in the urine to assess response to therapy. Ann Neurol (1977) 1.10
Association of homozygous C4B deficiency with bacterial meningitis. J Infect Dis (1989) 1.10
Measurement error of two different techniques for brain atrophy assessment in multiple sclerosis. Neurology (2004) 1.09